Navigation Links
Medarex Reports Phase 1/2 Clinical Data of MDX-060 in Lymphoma at American Association for Cancer Research Meeting
Date:4/16/2008

PRINCETON, N.J., April 16 /PRNewswire-FirstCall/ -- Medarex, Inc. (Nasdaq: MEDX) announced today data from a Phase 1/2 trial that suggest a potential association between higher doses of MDX-060, an investigational anti-CD30 antibody, and improvement in disease control and prolonged progression-free survival in patients with relapsed or refractory CD30- positive lymphomas. Results from the Phase 1/2 trial were presented at the Annual Meeting of the American Association for Cancer Research (AACR), being held April 12-16, 2008 in San Diego (Abstract #5525).

"We continue to assess the potential for anti-CD30 antibody therapies in the marketplace and are pleased with the findings of this exploratory study," said Howard H. Pien, President and CEO of Medarex. "We look forward to analyzing these results alongside the Phase 2 proof-of-concept chemotherapy combination data that is expected later in the year."

In the completed dose-escalation Phase 1/2 trial, 72 patients with relapsed or refractory CD30-positive lymphoma received weekly doses of MDX-060 (0.1, 1, 4, 10 or 15 mg/kg) for four weeks. Of the 33 patients treated at the two highest doses of MDX-060, disease control was observed in 51 percent of patients (3 complete responses, 14 stable disease), with median progression- free survival of 3.7 months and 39 percent of patients with no evidence of disease progression four months post-treatment. Of the 39 patients treated at the three lowest doses of MDX-060, disease control was observed in 33 percent of patients (1 complete response, 2 partial responses, 10 stable disease), with median progression-free survival of less than 2 months and 18 percent of patients with no evidence of disease progression four months post-treatment. MDX-060 treatment was well-tolerated with no clinically meaningful infusion reactions. The most frequently reported drug-related adverse events were fatigue and pyrexia considered to be mild to moderate in severity.

About Anti-CD30 Antibody Therapy

MDX-060 is a fully human antibody that targets CD30, a marker found on activated lymphocytes that is present on malignant cells of Hodgkin's disease (HD) as well as other CD30-expressing cancers. Medarex is currently conducting an ongoing Phase 2 proof-of-concept trial of MDX-060 in combination with gemcitabine for HD. Medarex is also developing MDX-1401, a second-generation non-fucosylated version of the MDX-060 parental antibody, that is enhanced for greater antibody-dependent cellular cytotoxicity and is being explored in a multi-dose, dose-escalation Phase 1 clinical trial for HD.

About Medarex

Medarex is a biopharmaceutical company focused on the discovery, development and potential commercialization of fully human antibody-based therapeutics to treat life-threatening and debilitating diseases, including cancer, inflammation, autoimmune disorders and infectious diseases. Medarex applies its UltiMAb(R) technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody product candidates for itself and its partners. More than 40 of these therapeutic product candidates derived from Medarex technology are in human clinical testing or have had INDs submitted for such trials, with seven of the most advanced product candidates currently in Phase 3 clinical trials or the subject of regulatory applications for marketing authorization. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs. For more information about Medarex, visit its website at http://www.medarex.com.

Medarex Statement on Cautionary Factors

Except for the historical information presented herein, matters discussed herein relating to Phase 1/2 clinical data of MDX-060 in lymphoma may constitute forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Statements that are not historical facts, including statements preceded by, followed by, or that include the words "potential"; "may"; or similar statements are forward-looking statements. Medarex disclaims, however, any intent or obligation to update these forward-looking statements. Risks and uncertainties include risks associated with product development, unforeseen safety issues resulting from the administration of antibody products in humans, as well as risks detailed from time to time in Medarex's public disclosure filings with the U.S. Securities and Exchange Commission (SEC), including its Annual Report on Form 10-K for the fiscal year ended December 31, 2007 and its quarterly reports on Form 10-Q. There can be no assurance that future milestone payments will be paid, whether the product development efforts will succeed, or whether other developed products will receive required regulatory clearance or that, even if such regulatory clearance were received, such products would ultimately achieve commercial success. Copies of Medarex's public disclosure filings are available from its investor relations department.

Medarex(R), the Medarex logo and UltiMAb(R) are registered trademarks of Medarex, Inc. All rights are reserved.


'/>"/>
SOURCE Medarex, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Medarex to Present at Thomas Weisel Partners Healthcare Conference 2007
2. Medarex to Present at the Bear Stearns 20th Annual Healthcare Conference
3. Medarex Announces Extension of Broad Antibody Development Relationship with Centocor
4. Medarex to Present at the A.G. Edwards 2nd Annual Emerging Growth Conference
5. Medarex to Present at the UBS Global Life Sciences Conference
6. Medarex Announces Election of Marc Rubin as New Board Member
7. Medarex to Present at the 26th Annual JPMorgan Healthcare Conference
8. Medarex Announces Completion of Sale of Shares in Genmab A/S
9. Medarex to Announce 2007 Fourth Quarter and Year-End Financial Results on Tuesday, February 26, 2008
10. Medarex to Present at the Susquehanna Financial Group Healthcare Conference
11. Medarex Announces Presentations at Annual Meeting of the American Association for Cancer Research
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/21/2017)... ... April 21, 2017 , ... The impressively ... focus of researchers, engineers, product developers, and industry suppliers gathered last week for ... SPIE, the international society for optics and photonics , the event drew ...
(Date:4/21/2017)... ... , ... Frederick Innovative Technology Center, Inc. (FITCI), a business ... earned a $77,518 grant from the Rural Maryland Council (RMC) to support refurbishment ... first incubator. A non-profit corporation, FITCI is a public-private partnership of the governments ...
(Date:4/20/2017)... April 20, 2017  Eli Lilly and Company (NYSE: ... evaluating galcanezumab for the prevention of migraine at the ... take place April 22-28, 2017, in Boston ... abstracts at AAN, including safety and patient outcomes data ... with a reduction in monthly migraine headache days among ...
(Date:4/20/2017)... Kong (PRWEB) , ... April 20, 2017 , ... NetDimensions ... Global Sales. , With over 20 years of experience in the learning technologies industry, ... a sister company within Learning Technologies Group plc (LTG). At LEO, Mastin served as ...
Breaking Biology Technology:
(Date:4/13/2017)... April 13, 2017 UBM,s Advanced Design and ... will feature emerging and evolving technology through its 3D ... will run alongside the expo portion of the event ... and demonstrations focused on trending topics within 3D printing ... and manufacturing event will take place June 13-15, 2017 at ...
(Date:4/11/2017)... April 11, 2017 Crossmatch®, a globally-recognized ... solutions, today announced that it has been awarded ... Projects Activity (IARPA) to develop next-generation Presentation Attack ... "Innovation has been a driving force within ... will allow us to innovate and develop new ...
(Date:4/11/2017)... , April 11, 2017 No two ... researchers at the New York University Tandon School ... Engineering have found that partial similarities between prints ... used in mobile phones and other electronic devices ... The vulnerability lies in the fact that ...
Breaking Biology News(10 mins):